Q2708568 (Q2708568): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The project concerns the expansion of the R & D department operating within the Radiopharmaceutical Production Centre in Krakow. The project will purchase the research equipment necessary to achieve the objectives of the R & D agenda. The purchased infrastructure will also be used in the quality control department of radiopharmaceuticals manufactured in the Radiopharmaceuticals Production Centre in Krakow.The project will also carry out work to...) |
||||||||||||||
| Property / summary | |||||||||||||||
The project concerns the expansion of the R & D department operating within the Radiopharmaceutical Production Centre in Krakow. The project will purchase the research equipment necessary to achieve the objectives of the R & D agenda. The purchased infrastructure will also be used in the quality control department of radiopharmaceuticals manufactured in the Radiopharmaceuticals Production Centre in Krakow.The project will also carry out work to increase the technical parameters of the cyclotron possessed, and thus to increase the production capacity and introduce a fundamental change regarding the production process.The research agenda assumes the carrying out of works in the field of Ga68 gala radiomarker produced in cyclotron and FDOPA technology.Chloride of Ga68 galaxy, radio marker used in diagnostics of prostate and neuroendocrine tumours.FDOPA is used in the diagnosis of the neuroendron syndrome and intent of the diagnosis of the nerosine syndrome and other diagnostics. Both Ga68 and FDOPA-labelled compounds are complementary radiomarks used in the diagnosis of neuroendocrine tumors.Implementation of the results of the agenda for Voxel’s activity will allow the launch of the production of innovative radiopharmaceutical products marked with Ga68 and FDOPA.The implementation of the agenda will allow for comprehensive diagnostics in the field of neuroendocrine tumors, providing information about the differentiation of tumors, the stage of progress and giving the opportunity to make further therapeutic decisions. (English) | |||||||||||||||
| Property / summary: The project concerns the expansion of the R & D department operating within the Radiopharmaceutical Production Centre in Krakow. The project will purchase the research equipment necessary to achieve the objectives of the R & D agenda. The purchased infrastructure will also be used in the quality control department of radiopharmaceuticals manufactured in the Radiopharmaceuticals Production Centre in Krakow.The project will also carry out work to increase the technical parameters of the cyclotron possessed, and thus to increase the production capacity and introduce a fundamental change regarding the production process.The research agenda assumes the carrying out of works in the field of Ga68 gala radiomarker produced in cyclotron and FDOPA technology.Chloride of Ga68 galaxy, radio marker used in diagnostics of prostate and neuroendocrine tumours.FDOPA is used in the diagnosis of the neuroendron syndrome and intent of the diagnosis of the nerosine syndrome and other diagnostics. Both Ga68 and FDOPA-labelled compounds are complementary radiomarks used in the diagnosis of neuroendocrine tumors.Implementation of the results of the agenda for Voxel’s activity will allow the launch of the production of innovative radiopharmaceutical products marked with Ga68 and FDOPA.The implementation of the agenda will allow for comprehensive diagnostics in the field of neuroendocrine tumors, providing information about the differentiation of tumors, the stage of progress and giving the opportunity to make further therapeutic decisions. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The project concerns the expansion of the R & D department operating within the Radiopharmaceutical Production Centre in Krakow. The project will purchase the research equipment necessary to achieve the objectives of the R & D agenda. The purchased infrastructure will also be used in the quality control department of radiopharmaceuticals manufactured in the Radiopharmaceuticals Production Centre in Krakow.The project will also carry out work to increase the technical parameters of the cyclotron possessed, and thus to increase the production capacity and introduce a fundamental change regarding the production process.The research agenda assumes the carrying out of works in the field of Ga68 gala radiomarker produced in cyclotron and FDOPA technology.Chloride of Ga68 galaxy, radio marker used in diagnostics of prostate and neuroendocrine tumours.FDOPA is used in the diagnosis of the neuroendron syndrome and intent of the diagnosis of the nerosine syndrome and other diagnostics. Both Ga68 and FDOPA-labelled compounds are complementary radiomarks used in the diagnosis of neuroendocrine tumors.Implementation of the results of the agenda for Voxel’s activity will allow the launch of the production of innovative radiopharmaceutical products marked with Ga68 and FDOPA.The implementation of the agenda will allow for comprehensive diagnostics in the field of neuroendocrine tumors, providing information about the differentiation of tumors, the stage of progress and giving the opportunity to make further therapeutic decisions. (English) / qualifier | |||||||||||||||
point in time: 7 July 2021
| |||||||||||||||
Revision as of 21:29, 7 July 2021
Project Q2708568 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q2708568 in Poland |
Statements
864,243.0 zloty
0 references
1,595,580.0 zloty
0 references
54.16 percent
0 references
21 January 2020
0 references
21 January 2022
0 references
VOXEL SPÓŁKA AKCYJNA
0 references
50°3'49.0"N, 19°56'31.2"E
0 references
Projekt dotyczy rozbudowy działu badawczorozwojowego działającego w obrębie Centrum Produkcji Radiofarmaceutyków w Krakowie.W ramach projektu zostanie zakupiona aparatura naukowobadawcza niezbędna do zrealizowania założeń agendy badawczorozwojowej. Zakupiona infrastruktura będzie również wykorzystywana w dziale kontroli jakości radiofarmaceutyków wytwarzanych w Centrum Produkcji Radiofarmaceutyków w Krakowie.W ramach projektu zostaną również przeprowadzone prace mające na celu zwiększenie parametrów technicznych posiadanego cyklotronu, a co za tym idzie zwiększeniem zdolności produkcyjnych oraz wprowadzenie zasadniczej zmiany dotyczącej procesu produkcyjnego.Agenda badawczorozwojowa zakłada przeprowadzenie prac w zakresie radioznacznika galowego Ga68 wytworzonego w technologii cyklotronowej oraz FDOPA.Chlorek galu Ga68, radioznacznik stosowany w diagnostyce prostaty oraz guzów neuroendokrynnych.FDOPA jest stosowana w diagnostyce zespołu Parkinsona oraz innych schorzeń neurologicznych, różnicowanie drżenia zamiarowego i różnicowanie zespołów Parkinsona oraz diagnostyce guzów neuroendokrynnych.Przeprowadzenie prac BR w zakresie dwóch powyżej wymienionych radioznaczników nie jest przypadkowe. Zarówno związki znakowane izotopem Ga68 jak i FDOPA są komplementarnymi dla siebie radioznacznikami stosowanymi w diagnostyce guzów neuroendokrynnych.Wdrożenie wyników agendy do działalności Voxel pozwoli na uruchomienie produkcji innowacyjnych produktów radiofarmaceutyki znakowane galem Ga68 oraz FDOPA.Realizacja agendy pozwoli na kompleksową diagnostykę w zakresie guzów neuroendokrynnych dającej informację o zróżnicowaniu guzów, stopniu zaawansowania oraz dającej możliwość podjęcie dalszych decyzji terapeutycznych. (Polish)
0 references
The project concerns the expansion of the R & D department operating within the Radiopharmaceutical Production Centre in Krakow. The project will purchase the research equipment necessary to achieve the objectives of the R & D agenda. The purchased infrastructure will also be used in the quality control department of radiopharmaceuticals manufactured in the Radiopharmaceuticals Production Centre in Krakow.The project will also carry out work to increase the technical parameters of the cyclotron possessed, and thus to increase the production capacity and introduce a fundamental change regarding the production process.The research agenda assumes the carrying out of works in the field of Ga68 gala radiomarker produced in cyclotron and FDOPA technology.Chloride of Ga68 galaxy, radio marker used in diagnostics of prostate and neuroendocrine tumours.FDOPA is used in the diagnosis of the neuroendron syndrome and intent of the diagnosis of the nerosine syndrome and other diagnostics. Both Ga68 and FDOPA-labelled compounds are complementary radiomarks used in the diagnosis of neuroendocrine tumors.Implementation of the results of the agenda for Voxel’s activity will allow the launch of the production of innovative radiopharmaceutical products marked with Ga68 and FDOPA.The implementation of the agenda will allow for comprehensive diagnostics in the field of neuroendocrine tumors, providing information about the differentiation of tumors, the stage of progress and giving the opportunity to make further therapeutic decisions. (English)
7 July 2021
0 references
Identifiers
RPMP.01.02.02-12-0135/19
0 references